174579-31-8

Basic information

• Product Name: TERT-BUTYL-4-AMINOPHENYLACETATE
• Synonyms: tert-Butyl 2-(4-aMinophenyl)acetate;2-(4-aMinophenyl)-3,3-diMethylbutanoate;4-Aminophenylacetic acid tert-butyl ester;4-AMino-benzeneacetic acid tert-butyl ester
• CAS NO: 174579-31-8
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.27
• Mol File: 174579-31-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 30-32°C
• Boiling Point: 310.6°Cat760mmHg
• Flash Point: 164.1°C
• Appearance: /
• Density: 1.067g/cm³
• Vapor Pressure: 0.000593mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: TERT-BUTYL-4-AMINOPHENYLACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL-4-AMINOPHENYLACETATE(174579-31-8)
• EPA Substance Registry System: TERT-BUTYL-4-AMINOPHENYLACETATE(174579-31-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 174579-31-8(Hazardous Substances Data)

Usage

General Description

"Tert-Butyl-4-aminophenylacetate" is a chemical compound with the molecular formula C12H17NO2. It is a white solid that is commonly used as a building block in organic synthesis and pharmaceutical manufacturing. tert-Butyl-4-aminophenylacetate is derived from 4-aminophenylacetic acid, which is a common starting material for the synthesis of various pharmaceuticals and organic compounds. Tert-Butyl-4-aminophenylacetate is known for its stability and relatively low reactivity, making it a valuable component in the production of various drugs and compounds. It is important to handle and store this chemical with care, as it can pose health and safety risks if not properly managed.

InChI:InChI=1/C12H17NO2/c1-12(2,3)15-11(14)8-9-4-6-10(13)7-5-9/h4-7H,8,13H2,1-3H3

Upstream product

• 29704-38-9 (4-nitrophenyl)acetic acid tert-butyl ester 
• 104-03-0 4-nitrobenzeneacetic acid 
• 106-40-1 4-bromo-aniline 
• 51656-70-3 (2-tert-butoxy-2-oxoethyl)zinc(II) bromide 

Downstream Products

• 181519-06-2 tert-butyl 2-(4-isocyanatophenyl)acetate 
• 1665292-90-9 C₃₁H₃₇N₃O₅ 
• 1621294-39-0 2-(4-(tert-butoxycarbonyl(2-(3,4-difluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)phenyl)acetic acid tert-butyl ester 
• 1621294-37-8 tert-butyl 2-(4-(tert-butoxycarbonyl(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)phenyl)acetate 
• 1621293-97-7 2-(4-(2-(3,4-difluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)phenyl)acetic acid 
• 1436866-26-0 2-[4-[(2-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]phenyl]acetic acid 
• 1621294-35-6 tert-butyl 2-(4-(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)phenyl)acetate 
• 1469894-72-1 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-(4-(2-tert-butoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate 

Relevant articles and documents

PYRIDAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof. In particular, disclosed in the present invention are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing Janus kinase-mediated related diseases, in particular autoimmune diseases, inflammatory diseases and cancers, by means of using the compound or the pharmaceutically acceptable salt thereof, and a method for preparing the compound or the pharmaceutically acceptable salt thereof. Each substituent of general formula (I) has the same definition as that in the description.

Coupling of Reformatsky Reagents with Aryl Chlorides Enabled by Ylide-Functionalized Phosphine Ligands

The coupling of aryl chlorides with Reformatsky reagents is a desirable strategy for the construction of α-aryl esters but has so far been substantially limited in the substrate scope due to many challenges posed by various possible side reactions. This limitation has now been overcome by the tailoring of ylide-functionalized phosphines to fit the requirements of Negishi couplings. Record-setting activities were achieved in palladium-catalyzed arylations of organozinc reagents with aryl electrophiles using a cyclohexyl-YPhos ligand bearing an ortho-tolyl-substituent in the backbone. This highly electron-rich, bulky ligand enables the use of aryl chlorides in room temperature couplings of Reformatsky reagents. The reaction scope covers diversely functionalized arylacetic and arylpropionic acid derivatives. Aryl bromides and chlorides can be converted selectively over triflate electrophiles, which permits consecutive coupling strategies.

Palladium-catalyzed α-arylation of zinc enolates of esters: Reaction conditions and substrate scope

The intermolecular α-arylation of esters by palladium-catalyzed coupling of aryl bromides with zinc enolates of esters is reported. Reactions of three different types of zinc enolates have been developed. α-Arylation of esters occurs in high yields with i